Treatment aiming to enhance bone tissue regeneration can benefit from multiple growth factor or small molecule delivery. In the present study, the objective was to evaluate the feasibility of using nanocomposite fibrous scaffold to deliver prostacyclin I2 agonist ONO-1301 in combination with BMP2 for treating critical sized bone defect. For this, ONO-1301 at three different concentrations (1.67 μg, 5 μg, 15 μg) and a fixed dose of BMP2 (5 μg) was loaded on the scaffold via physical adsorption. The results showed fast release of ONO-1301 for two weeks, whereas BMP2 exhibited slow and sustained release for four weeks. The scaffold with dual factors promoted the migration and osteogenic differentiation of mesenchymal stem cells (MSCs) in vitro when compared to the scaffold with BMP2 alone. It also augmented bone tissue regeneration in critical sized rat calvarial defect at 12 weeks; mainly with lower dose of ONO-1301. However, synergistic effect on osteogenic differentiation and bone regeneration were not obtained through the concurrent release of BMP-2 and ONO-1301.
S. Kuttappan, Jo, J. -ichiro, Sabu, C. K., Dr. Deepthy Menon, Tabata, Y., and Dr. Manitha B. Nair, “Bioinspired Nanocomposite Fibrous Scaffold Mediated Delivery of ONO-1301 and BMP2 Enhance Bone Regeneration in Critical Sized Defect”, Materials Science and Engineering: C, vol. 110, p. 110591, 2020.